Head-to-head · WeighScore
Enhance MD vs Vida Health
The verdict
Enhance MD takes it — 84.8/100 to 55.2/100.
Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Enhance MD | Vida Health |
|---|---|---|
| WeighScore | 84.8/100 | 55.2/100 |
| Grade | B | C |
| Site position | #5 | #494 |
| Semaglutide | $249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay | Not disclosed |
| Tirzepatide | $329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay | Not disclosed |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #5 · B
Strengths
- Transparent tiered pricing across sema, tirz, microdose, and combo
- Dose-flat — the price does not step up as you titrate
- Six-month lab testing plus provider-led care
- NAD+ longevity adjacency available
Where it loses points
- Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
- No oral or sublingual route
- States served are not published
- Higher entry price than the cheapest compounded programs
Site position #494 · C
Strengths
- Medical Weight Loss program includes anti-obesity GLP-1 medications
- Pairs medication with behavioral-health coaching and medical management
- Whole-person care across chronic conditions, sleep, and nutrition
- Integrates with major health plans, PBMs, and benefit platforms
- Established virtual chronic-care platform
Where it loses points
- Distributed mainly via employers and health plans, not direct cash-pay
- Access usually requires employer or plan sponsorship
- No public consumer GLP-1 pricing
- Clinician credentials not detailed publicly
- Less suited to consumers wanting direct-to-door GLP-1
Featured provider
Enhance MD
Enhance MD scores 84.8/100 (B). A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.